PubMed Health⌕ Search

Biomedical subjects

R Posse

Publications and source records attributed to R Posse.

4 recordsLinked to original sources
PubMed1990

[Diastolic function in Chagas disease].

With the purpose of analyzing diastolic function in Chagas, disease (ECh), 42 patients were studied: 31 males (aged 33 +/- 9), 22 of them with positive serology for ECh and 9 with negative serology; 11 female patients (aged 36 +/- 12), 10 with positive serology and 1 with negative serology. In all patients 2 D-Echo and simultaneous EKG, phonocardiogram, apexcardiogram and M-mode Echo at 100 mm/sec were taken. The A2-D, A2-O (total apexcardiographic relaxation-RAT), a/D (diastolic amplitude of "a" wave), ITRAT = A2 - C/RAT, DDVI, DSVI, shortening fraction (FA) and percentage of dimension changes (D D%) were determined. The patients were divided into 4 groups: G - A (n = 10) normal; G - B (n = 15) positive serology, with EKG and Rx and FA normal; G - C (n = 10) positive serology, abnormal EKG, and normal Rx and FA; G - D (n = 7) positive serology, abnormal EKG, mild cardiomegalia and diminished FA. The patients from group B presented significative modification, 46& (7/15) of the FD indexes and those from group D with 70% (5/7), as well as of D D C - E and D D Dm-0 indicative of uncoordinated contraction and relaxation. A progressive worsening of the FD from G - D was observed, reaching in this last one statistically significant values. In the ECh the alterations in the FD precede the systolic, which allows for an early detection of myocardiac damage by noninvasive techniques.

Adult↗
PubMedDate not supplied

[Comparative multicenter clinical study of flecainide and amiodarone in the treatment of ventricular arrhythmias associated with chronic Chagas cardiopathy].

Eighty one patients with ventricular arrhythmias associated with chronic Chagas disease participated in this multi-clinic study. Treatment with Amiodarone and Flecainide were compared using an open, parallel, randomized experimental design. Inclusion criteria required the selected patients to have 1,200 premature ventricular contractions per 24 hours and/or repetitive ventricular arrhythmias. Patients received 60 days of treatment with either Flecainide at 200 to 400 mg per day or Amiodarone 800 to 400 mg per day. This dosage was adjusted to the therapeutic response. Clinical and laboratory evaluations, electrocardiogram and 24 hour Holters were performed at study days: -7, -1, 8/9, 15/16 and 59/60. The percentage reduction of premature ventricular contractions at days 9, 16 and 60 were: 73.1%, 82.9% and 92.4% with Flecainide and 77.6%, 90.1% and 90.7% with Amiodarone. At the end of the study, Flecainide had induced a 92.5% reduction in couplets and 96.5% reduction in ventricular tachycardia. For the same parameters the percentages following Amiodarone were 95.2% and 92.6% respectively. Treatment was discontinued in three patients in the Flecainide group (two because of prolonged sinus node bradycardia and one because of sustained ventricular tachycardia). In the Amiodarone group, treatment was discontinued also in three patients (one because of sustained ventricular tachycardia and two because of severe photosensitive dermatosis). Although there were some differences in the results form center to center, the conclusions from the overall data indicate a similar, therapeutic effect with both drugs.

Adolescent↗